BioLife Solutions Inc (NASDAQ:BLFS) VP Todd Berard sold 3,000 shares of the firm’s stock in a transaction dated Wednesday, May 15th. The stock was sold at an average price of $16.96, for a total value of $50,880.00. Following the sale, the vice president now directly owns 44,074 shares in the company, valued at $747,495.04. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Todd Berard also recently made the following trade(s):

  • On Monday, April 15th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $17.56, for a total value of $52,680.00.
  • On Thursday, March 14th, Todd Berard sold 3,000 shares of BioLife Solutions stock. The stock was sold at an average price of $16.67, for a total value of $50,010.00.

BioLife Solutions stock traded up $0.48 during midday trading on Friday, hitting $18.22. 129,539 shares of the company were exchanged, compared to its average volume of 117,310. The firm has a market cap of $342.54 million, a price-to-earnings ratio of 130.14 and a beta of 1.53. BioLife Solutions Inc has a fifty-two week low of $8.50 and a fifty-two week high of $26.35. The company has a quick ratio of 12.99, a current ratio of 14.50 and a debt-to-equity ratio of 0.02.

BioLife Solutions (NASDAQ:BLFS) last issued its quarterly earnings results on Thursday, May 9th. The medical equipment provider reported $0.03 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.03. The company had revenue of $5.77 million for the quarter, compared to the consensus estimate of $5.67 million. BioLife Solutions had a return on equity of 10.32% and a net margin of 17.01%. Equities analysts expect that BioLife Solutions Inc will post 0.13 EPS for the current year.

BLFS has been the topic of several analyst reports. BidaskClub raised BioLife Solutions from a “hold” rating to a “buy” rating in a report on Tuesday, March 19th. ValuEngine raised BioLife Solutions from a “hold” rating to a “buy” rating in a report on Thursday, January 31st. Finally, Zacks Investment Research lowered BioLife Solutions from a “buy” rating to a “hold” rating in a report on Tuesday, March 12th. One research analyst has rated the stock with a hold rating and six have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $18.20.

Hedge funds have recently modified their holdings of the business. Cowen Prime Services LLC purchased a new position in BioLife Solutions during the first quarter worth approximately $63,000. Ladenburg Thalmann Financial Services Inc. boosted its position in BioLife Solutions by 281.3% during the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 5,380 shares of the medical equipment provider’s stock worth $96,000 after purchasing an additional 3,969 shares in the last quarter. Canton Hathaway LLC purchased a new position in BioLife Solutions during the fourth quarter worth approximately $66,000. Signaturefd LLC purchased a new position in BioLife Solutions during the first quarter worth approximately $161,000. Finally, Morgan Stanley boosted its position in BioLife Solutions by 114.8% during the first quarter. Morgan Stanley now owns 9,793 shares of the medical equipment provider’s stock worth $175,000 after purchasing an additional 5,234 shares in the last quarter. Institutional investors own 41.21% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Todd Berard Sells 3,000 Shares of BioLife Solutions Inc (BLFS) Stock” was reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.watchlistnews.com/todd-berard-sells-3000-shares-of-biolife-solutions-inc-blfs-stock/3015083.html.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets grade cell and tissue hypothermic storage and cryopreservation freeze media products for cells, tissues, and organs in the United States. Its products are serum-free and protein-free solutions, which are formulated to reduce preservation-induced cell damage and death.

Read More: Stock Ratings and Recommendations: Understanding Analyst Upgrades and Downgrades

Insider Buying and Selling by Quarter for BioLife Solutions (NASDAQ:BLFS)

Receive News & Ratings for BioLife Solutions Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLife Solutions and related companies with MarketBeat.com's FREE daily email newsletter.